- Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a follow-up order, valued at over A$900,000, from Univo Pharmaceuticals
- The Israel-based medicinal cannabis company has ordered Mernova’s premium, cured and hand-trimmed dried medicinal cannabis flower
- The shipment delivery is expected to be completed once an export permit has been granted by Health Canada
- Israel is considered to be a rapidly-growing medicinal cannabis market that is set to be worth roughly A$90.3 billion by 2024
- Company shares are up 8.33 per cent on the back of this morning’s news and are trading for 3.3 cents each
Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a US$625,690 (roughly A$901,830) purchase order from Univo Pharmaceuticals.
Univo is an Israel-based medicinal cannabis company which holds a licence for the entire supply chain, including cultivation, production, research and development, and distribution.
The Israeli company has ordered Mernova’s premium, cured and hand-trimmed dried medicinal cannabis flower.
This marks Mernova’s second purchase order from Univo, with the first announced on April 1 this year.
“Following our initial entry into the Israeli market in April this year, we are delighted to have received another significant purchase order from Univo which further strengthens our penetration into this growing market,” CEO and Co-Founder Dr Miri Halperin Wernli said.
Mernova will ship four of its premium strains of cured, hand-trimmed, dried medicinal cannabis flower to Univo in Israel.
Read the article in by Jessica De Freitas in The Market Herald.